Moreover, the Acetic acids/FFAR2 axis enhanced the expression of Arg1 through the Calcium/PPAR-γ pathway, suggesting inhibitors or modulators targeting Calcium/PPAR-γ or SCFA excess in combination with anti-PD-1 antibodies will have potential clinical value in improving cancer treatment. Here, ARG1 is linked to cancer.